<DOC>
	<DOCNO>NCT01399606</DOCNO>
	<brief_summary>This multicentric International Phase III , Long term open label study ( 12 month ) assess long-term safety efficacy BF2.649 ( Pitolisant ) treatment Excessive Daytime Sleepiness ( EDS ) narcoleptic patient without cataplexy .</brief_summary>
	<brief_title>Long Term Open Label Study Narcolepsy With BF2.649 ( Pitolisant )</brief_title>
	<detailed_description>In narcoleptic patient , result obtain previous study show BF2.649 reduce significantly diurnal somnolence compare placebo confirm waken effect EDS demonstrate anti-cataplectic effect administrate individual titration scheme establish basis individual benefit/tolerance ratio.This long-term safety pragmatic study provide information long-term treatment BF2.649 , also allow patient satisfy BF2.649 treatment previous on-going study Bioprojet continue benefit product.This open-label , naturalistic pragmatic , prospective longitudinal uncontrolled , multi-centre international trial assess safety effect long-term therapy BF2.649 treatment excessive daytime sleepiness narcolepsy , 12-month follow-up .</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Cataplexy</mesh_term>
	<criteria>Males female , age 18 year old . Patients diagnosis narcolepsy accord International Classification Sleep Disorders ( ICSD2 ) criterion . Patients complain EDS ESS score least 12 ( historical assessment ) . Patients previously participate complete Bioprojet narcolepsy study assess BF2.649 efficacy ( P0503 , P0606 , P0703 HARMONY I P0707 HARMONY II , P0915 HARMONY I bis ) narcoleptic patient complain EDS opinion investigator would able participate double blind study placebo could benefit test new therapy BF2.649 open label study . patient receive BF2.649 ( Pitolisant ) condition '' ATU nominative '' accord French law ( call name temporary authorization use approve Afssaps ) Excessive Daytime Sleepiness associate narcolepsy . Patients discontinue study treatment previous study due adverse event related BF2.649 . Patients untreated sleep apnoea syndrome cause daytime sleepiness Patients work occupation require variable shift work routine night shift . Psychiatric neurological disorder , narcolepsy/cataplexy , problem investigator 's opinion would preclude patient 's participation completion trial comprise reliable representation subjective symptom . Current recent ( within one year ) history substance abuse dependence disorder include alcohol abuse define DSMIV . Other active clinically significant illness , include unstable cardiovascular , neoplasic pathology could interfere study conduct counterindicate study treatment place patient risk trial compromise study participation . Known history long QTc syndrome , syncope arrhythmia significant serious abnormality ECG ( e.g . recent myocardial infarction ) , QTc interval strictly high 450 m ( electrocardiogram Bazett 's correct QT interval Severe Hepatic Impairment Severe Renal Impairment , significant abnormality physical examination clinical laboratory result . Known hypersensitivity test treatment include active substance excipients . Participation study 30 day prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Excessive Daytime Sleepiness ( EDS )</keyword>
	<keyword>Narcolepsy</keyword>
</DOC>